Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab
Sign Up to like & getrecommendations! Published in 2019 at "Vox Sanguinis"
DOI: 10.1111/vox.12864
Abstract: Daratumumab (DARA) is a human monoclonal antibody for the treatment of multiple myeloma (MM). DARA binds to CD38 on RBCs and interferes with detection of RBC alloantibodies. The objective of this study was to evaluate… read more here.
Keywords: multiple myeloma; rbc alloimmunization; risk rbc; patients treated ... See more keywords